WorthPointe’s AstraZeneca AZN Stock Holding History

WorthPointe’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,373	Closed	-$214K	–	92
2024 Q3	$214K	Buy	+1,373	New	+$222K	0.09%	73

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

WorthPointe's AZN Position: Q4 2024 in Review

WorthPointe sold out of AstraZeneca (AZN) in Q4 2024, closing a stake of 1,373 shares — an estimated $214K sold.

WorthPointe first reported a position in AZN in Q3 2024 and held it in 1 quarter. The position peaked at $214K in Q3 2024. 1,219 funds tracked by Wall St. Rank hold AZN as of Q4 2024.

WorthPointe reported no remaining AstraZeneca position as of Q4 2024 after selling out during the quarter.
WorthPointe sold 1,373 AstraZeneca shares in Q4 2024, an estimated $214K.
WorthPointe first reported a position in AstraZeneca in Q3 2024 and held it in 1 quarter.
WorthPointe's AstraZeneca position peaked at $214K in Q3 2024.
1,219 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2024.

Based on WorthPointe's 13F filing for Q4 2024, filed 11 Feb 2025.